ALLO News - Candlesense

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (A...

Investor

13 days ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (A...

What macro‑economic or sector‑specific factors (e.g., biotech funding environment, FDA policy shifts) could amplify or mitigate the impact of this earnings release on the stock? How might the sentiment rating of 10 and the positive tone of the release translate into analyst upgrades or target price revisions? Is there any guidance on potential dilutive events (stock offerings, convertible debt) that could impact shareholder equity?

Earnings

27 days ago